[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kardigan, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632259","phase-2-study-of-efficacy-and-safety-of-tonlamarsen-in-participants-with-a-recent-hospitalization-and-a-concurrent-episode-of-acute-severe-hypertension-100632259",false,"NCT07511361","Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","KARDINAL-ASH","Key Inclusion Criteria:\n\n* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg\u002Fm2\n* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and\u002For treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and\u002For DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization\n* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg\n* Presence of established cardiovascular or renal disease\n\nKey Exclusion Criteria:\n\n* Has known history of secondary hypertension\n* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)\n* Has abnormal thyroid function with clinical significance\n* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening\n* History of and\u002For obvious clinical signs or symptoms of cirrhosis or other significant liver disease\n* Alanine aminotransferase or aspartate aminotransferase \\>2 x upper limit of normal\n* Most recent hospitalization was for non-cardiovascular or non-renal conditions","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.",[27,28,29,30],"Hypertension","Acute Severe Hypertension","Hypertensive Emergency","Hypertensive Urgency","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-23",{"date":39,"type":21},"2027-02",{"name":41,"class":42},"Kardigan, Inc.","INDUSTRY",8,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100609143","phase-2-a-study-of-the-efficacy-and-safety-of-danicamtiv-in-participants-with-symptomatic-genetic-and-familial-dilated-cardiomyopathy-100609143","NCT07210723","A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy","A Phase 2b\u002F3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy","KINSHIP-DCM","Key Inclusion Criteria:\n\n1. Has a diagnosis of DCM due to probable disease-causing variants of MYH7, TTN, or other identified genetic DCM variants, or with familial DCM\n2. Has New York Heart Association (NYHA) Class II-IV at Screening with stable symptoms for ≥1 month.\n3. Has at least mild left ventricular enlargement (LVE) and has adequate acoustic windows to enable accurate TTEs according to the Echocardiography Core Laboratory.\n4. Has a LVEF of ≤45%.\n5. Is on stable doses of maximally tolerated standard-of-care heart failure (HF) therapies reflecting current guidelines for at least 4 weeks prior to the first visit.\n6. Has DCM not attributed to substance abuse, amyloidosis, sarcoidosis, or any other secondary form of cardiomyopathy per the Investigator.\n7. Can perform an upright cardiopulmonary exercise training (CPET) with a peak oxygen uptake (pV̇O2) of 80% or less of predicted for a healthy individual and respiratory exchange ratio (RER) of ≥1.05\n\nKey Exclusion Criteria:\n\n1. Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator.\n2. Recent (\\\u003C90 days) clinically significant cardiac events, including acute coronary syndrome, hemodynamically significant epicardial coronary disease (per Investigator), coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft \\[CABG\\]), or hospitalization for heart failure\u002Fintravenous (IV) diuretic use.\n3. Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of left ventricle (LV) function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. \\> 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function.\n4. Unstable or untreated severe ventricular arrythmia (eg, ventricular tachycardia or ventricular fibrillation).\n5. History of malignancy of any type within 5 years prior to Screening\n6. Severe renal insufficiency (defined at the time of Screening as current estimated glomerular filtration rate \\[eGFR\\] \\\u003C15 mL\u002Fmin\u002F1.73m2 by simplified Modification of Diet in Renal Disease equation \\[sMDRD\\]).\n7. History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Sponsor, would pose a risk to participant safety or interfere with the study evaluation\n8. History of heart transplantation or anticipated heart transplantation in the next 6 months.\n9. Ongoing or anticipated advanced cardiac interventions, including chronic IV inotropic therapy, planned cardiac resynchronization therapy (CRT) or major surgery, or current\u002Fanticipated ventricular assist device placement within 6 months\n10. Clinically significant laboratory abnormalities at Screening",{"count":53,"type":21},332,[24,55],"PHASE3","The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.\n\nThe purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).\n\nThe main goals of the study are:\n\n* To assess the effect of danicamtiv on cardiac function using echocardiogram.\n* To evaluate the impact of danicamtiv on exercise capacity\n* To evaluate the safety and tolerability of danicamtiv\n\nParticipants will:\n\n* Take danicamtiv or placebo every day for approximately 6 months\n* Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up",[58],"Symptomatic Genetic Dilated Cardiomyopathy","2026-06-01",{"date":61,"type":35},"2026-06-03",{"date":63,"type":35},"2026-02-13",{"date":65,"type":21},"2028-01",{"name":41,"class":42},43,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100593081","phase-2-ataciguat-for-slowing-the-progression-of-moderate-calcific-aortic-valve-stenosis-a-randomized-placebo-controlled-study-100593081","NCT07001800","Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study","A Phase 2b\u002F3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis","KATALYST-AV","Key Inclusion Criteria:\n\n1. Adult male or female at least 50 years of age\n2. Has moderate CAVS as defined by:\n\n   1. An AVA of ≥1.0 cm2 to ≤1.50 cm2\n   2. An AVC score between \\>300 to 1200 Agatston units (AU) for women and between \\>300 to 2000 AU for men\n3. Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Imaging Core Laboratory\n4. For participants in CPET sub-study in Part A and all participants in Part B: If on beta blockade, the dose must be stable for at least 90 days prior to the Screening Visit with no anticipated changes during the study\n\nKey Exclusion Criteria:\n\n1. For participants in the CPET sub-study in Part A and all participants in Part B: Has any medical or physical condition that, in the Investigator's opinion, could lead to an inability to complete Protocol-required CPET procedures (eg, pulmonary disease, joint, leg, hip, back conditions that limit physical activity, or other absolute contraindications for CPET)\n2. Anticipated or planned prior aortic valve replacement, repair, surgery, or intervention in the next 6 months\n3. Has moderate, moderate-to-severe, or severe (Grade 2 or higher) mitral stenosis, mitral regurgitation, and\u002For aortic regurgitation\n4. Has suspected or known congenital aortic valve disease including bicuspid aortic valve\n5. New York Heart Association (NYHA) Class IV heart failure symptoms and\u002For requires continuous inotropes\n6. Has history of hypertrophic, genetic\u002Ffamilial cardiomyopathy or cardiomyopathy related to amyloid or sarcoid\n7. Has untreated obstructive coronary artery disease or anticipating coronary stenting surgery\n8. Abnormal electrocardiogram (ECG) results or long-standing persistent or permanent atrial fibrillation","50 Years",{"count":78,"type":21},1276,[24,55],"The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.",[82],"Moderate Aortic Valve Stenosis",[84,85,86,87,88,89,90,91,92],"Ataciguat","sGC activator","sGC stimulator","Aortic valve stenosis","Moderate aortic valve stenosis","Calcific aortic valve stenosis","CAVS","Moderate Calcific Aortic Valve Stenosis","Aortic Stenosis (AS)","2026-05-04",{"date":95,"type":35},"2026-05-06",{"date":97,"type":35},"2025-06-27",{"date":99,"type":21},"2030-09-30",{"name":41,"class":42},70,""]